<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592484</url>
  </required_header>
  <id_info>
    <org_study_id>CDK-002-101</org_study_id>
    <nct_id>NCT04592484</nct_id>
  </id_info>
  <brief_title>A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors</brief_title>
  <official_title>A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Codiak BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Codiak BioSciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, Phase 1/2 open-label, multicenter, dose escalation, safety,&#xD;
      pharmacodynamic, and PK study of CDK-002 in subjects with advanced/metastatic, recurrent,&#xD;
      injectable solid tumors, whose disease has progressed despite receiving standard of care&#xD;
      treatment. CDK 002 will be administered intratumorally (IT).&#xD;
&#xD;
      Part A will enroll subjects with advanced/metastatic, recurrent, injectable solid tumors with&#xD;
      emphasis on head and neck squamous cell cancer (HNSCC), triple negative breast cancer (TNBC),&#xD;
      anaplastic thyroid carcinoma (ATC) and cutaneous squamous cell carcinoma (cSCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of ascending doses of CDK-002</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Incidence of treatment-emergent adverse events as assessed by CTCAE</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>CDK-002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDK-002</intervention_name>
    <description>CDK-002 administered intratumorally</description>
    <arm_group_label>CDK-002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria for Inclusion:&#xD;
&#xD;
          1. Age ≥ 18 years at the time of signing the informed consent form.&#xD;
&#xD;
          2. Histologically confirmed advanced, recurrent or metastatic injectable solid tumor and&#xD;
             has received the following prior therapy:&#xD;
&#xD;
               1. HNSCC: Subject must have been previously treated with a platinum-based&#xD;
                  chemotherapy regimen and/or a programmed cell death-protein 1 (PD-1) inhibitor.&#xD;
&#xD;
               2. TNBC: Subject must have been treated with at least 1 chemotherapy regimen and/or&#xD;
                  PD-L1 or PD-1 inhibitor for metastatic disease.&#xD;
&#xD;
               3. ATC: Subject must be considered inoperable and not considered to benefit from&#xD;
                  additional chemotherapy and/or radiation.&#xD;
&#xD;
               4. cSCC: Subject must have previously been treated with radiation therapy and/or&#xD;
                  chemotherapy and/or PD-L1 or PD-1 inhibitor.&#xD;
&#xD;
               5. Subjects with other advanced solid tumors that have progressed following standard&#xD;
                  therapy or for which there is no standard of care therapy with an overall&#xD;
                  survival (OS) benefit.&#xD;
&#xD;
          3. Measurable disease per RECIST v1.1 and ≥1 lesion that is measurable (ie, ≥1.0 cm by&#xD;
             CT, MRI, or ruler or caliper measurements for cutaneous lesions or other superficial&#xD;
             lesions in longest diameter [non-lymph nodes] or ≥1.5 cm in shortest diameter for&#xD;
             lymph nodes) and amenable to tumoral injection and biopsy per Investigator assessment.&#xD;
&#xD;
          4. Agrees to have a pre-treatment tumor biopsy within 7 days prior to the first dose of&#xD;
             CDK-002, and 2 on-treatment tumor biopsies of the same lesion. Biopsies may be core&#xD;
             needle, incisional, or excisional biopsies. For cutaneous lesions, a punch biopsy may&#xD;
             be acceptable. Fine needle aspiration (FNA) is not acceptable.&#xD;
&#xD;
          5. Understands and can comply with the study requirements and has signed the informed&#xD;
             consent form.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.&#xD;
&#xD;
          7. Life expectancy of at least 3 months.&#xD;
&#xD;
          8. Acceptable liver function.&#xD;
&#xD;
          9. Acceptable renal function.&#xD;
&#xD;
         10. Acceptable hematologic status.&#xD;
&#xD;
         11. Negative serum pregnancy test (for women of child-bearing potential) within 72 hours&#xD;
             before the first dose of CDK-002.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Criteria for Exclusion:&#xD;
&#xD;
          1. Prior treatment with a STING agonist.&#xD;
&#xD;
          2. Cytotoxic chemotherapy, biologic agents, investigational agents, or radiation therapy&#xD;
             within 4 weeks prior to the first dose of CDK 002 (6 weeks for nitrosoureas or&#xD;
             mitomycin C). The interval can be reduced to 2 weeks for bone-only radiation therapy.&#xD;
&#xD;
          3. Small-molecule kinase inhibitors or hormonal anticancer agents within 14 days prior to&#xD;
             the first dose of CDK 002.&#xD;
&#xD;
          4. Clinically significant ongoing AEs that have not returned to baseline or to Grade 1&#xD;
             NCI CTCAE v5.0.&#xD;
&#xD;
          5. Immunosuppressive agents including corticosteroids within 14 days of first dose of CDK&#xD;
             002. Topical, intranasal or inhaled corticosteroids, physiologic doses of systemic&#xD;
             steroids or limited treatment with systemic steroids (ie, for IV contrast prophylaxis)&#xD;
             may be administered with Sponsor approval.&#xD;
&#xD;
          6. Major surgery within 6 weeks or minor surgery (excluding tumor biopsies) within 14&#xD;
             days prior to the first dose of CDK 002 or if subject has not clinically recovered.&#xD;
&#xD;
          7. Clinically active central nervous system (CNS) metastases or carcinomatous meningitis.&#xD;
             Subjects with stable brain metastasis may be enrolled with Sponsor approval.&#xD;
&#xD;
          8. Metastatic liver involvement that exceeds one-third of total liver volume.&#xD;
&#xD;
          9. Clinically significant cardiovascular disease including but not limited to New York&#xD;
             Heart Association Class III or IV heart failure, myocardial infarction or stroke&#xD;
             within the past 6 months prior to the first dose of CDK 002, uncontrolled arrhythmia,&#xD;
             or severe aortic stenosis. Sponsor approval of subjects with an arrhythmia is&#xD;
             required.&#xD;
&#xD;
         10. History of myocarditis.&#xD;
&#xD;
         11. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic&#xD;
             therapy. Prophylactic antibiotics are acceptable.&#xD;
&#xD;
         12. Prior organ or stem cell transplant.&#xD;
&#xD;
         13. Primary immune deficiency.&#xD;
&#xD;
         14. Pregnant or nursing women.&#xD;
&#xD;
         15. Active Hepatitis B or C infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Hill</last_name>
    <phone>650-732-0943</phone>
    <email>wendy.hill@codiakbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Pat</last_name>
      <phone>480-323-1796</phone>
      <email>pshannon@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Frank Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University/CUMC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Vann</last_name>
      <phone>212-305-5098</phone>
      <email>ev2480@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Ingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Louie</last_name>
      <phone>215-220-9668</phone>
      <email>Jennifer.Louie2@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Roger Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia De Leon</last_name>
      <phone>210-580-9521</phone>
      <email>cdeleon@nextoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anthony Tolcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre/ Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Mason</last_name>
      <phone>+44 (0) 41 301 7215</phone>
      <email>sophie.mason@Glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Jeff Evans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Headington</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Cousins</last_name>
      <phone>+44 (0) 865 572 048</phone>
      <email>trialadministrator08@oncology.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Eileen Parkes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abigail Crowhurst</last_name>
      <phone>+44 (0) 208 642 6011</phone>
      <phone_ext>4020</phone_ext>
      <email>Abigail.Crowhurst@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Kevin Harrington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Walker</last_name>
      <phone>+44 (0) 161 918 7872</phone>
      <email>s.walker21@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Donna Graham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

